Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
Healthcare
$7.04 +0.99%
+$0.09 today
- Market cap
- $590.04M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
52W Low $1.94High $11.61
Volume 1.13M
Average 1.07M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$27.21M
FY 2025 · Annual
Net Income
-$29.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 364.5K |
| Gross Profit | 0 | 0 | 0 | 0 | (364.5K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.53K | 4.2M | 8.74M | 11.29M | 16.26M |
| Selling, General & Admin | 1.23M | 4.02M | 7.41M | 11.38M | 13.7M |
| Operating Expenses | 1.35M | 8.22M | 16.14M | 22.67M | 26.85M |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| EBITDA | (24.2M) | (8.22M) | (15.56M) | (21.54M) | (29.04M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.35M) | (8.22M) | (16.14M) | (22.67M) | (27.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 572.01K | 1.02M | 555.53K |
| Interest Expense | 179.85K | 497 | 0 | 0 | 0 |
| Other Income / Expenses | (23.03M) | (497) | 572.01K | 1.02M | (2.19M) |
| Income Before Tax | (24.38M) | (8.22M) | (15.57M) | (21.66M) | (29.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 6.01K | 10.27K | 26.42K | 41.04K | 37.72K |
| Net Income | (24.38M) | (8.23M) | (15.43M) | (21.61M) | (29.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| EPS (Diluted) | (6.64) | (0.59) | (0.89) | (0.76) | (0.89) |
| 3.67M | 13.89M | 17.34M | 28.29M | 32.97M | |
| 3.67M | 13.89M | 17.34M | 28.29M | 32.97M |
IMMX Earnings Waterfall · TTM
NASDAQ:IMMX · Revenue to Net Income
Key Ratios
EPS$-0.92
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$35.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.92, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Oct 27, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 424B5 | 424B5 filing | Sep 29, 2026 |
How much revenue does IMMX generate?
Immix Biopharma, Inc. (IMMX) reported $0.00 of revenue in fiscal 2025.
Is IMMX profitable?
Immix Biopharma, Inc. (IMMX) reported -$29.44M of net income.
Continue the stock analysis
Jump to another research area for this company.